News | July 22, 2025
AstraZeneca plans to invest $50 billion in US by 2030
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
Neuberg group commits to invest over Rs. 100 crores to start diagnostics facilities across Jharkhand in the next 2-3 years
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
The campaign celebrates radiant, healthy skin that shines naturally, empowering women to step forward with confidence in every walk of life.
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
India’s nutraceutical industry is expected to reach over US$ 22 billion in 2025
Subscribe To Our Newsletter & Stay Updated
